Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10486 | 0.83 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9APIK3R1 | |
| SCHEMBL29748409 | 0.83 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9APIK3R1 | |
| SCHEMBL11781360 | 0.79 | CYP2A6 (0.41) | DYRK1ASMN1; SMN2NPC1RAB9APIK3R1 | |
| SCHEMBL24425916 | 0.77 | DYRK1A (0.72) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL1798498 | 0.74 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL1586683 | 0.74 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL926971 | 0.74 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL354233 | 0.74 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL24218492 | 0.74 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL116288 | 0.74 | DYRK1A (0.58) | DYRK1ASMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108989-B | Resveratrol derivative and preparation method and application thereof | 山东大学 | 2024-04-05 | — | — | CN | claimed |
| CN-116640132-A | Coumarin fluorescent probe based on benzoxazole derivative and application thereof | 常州大学 | 2023-08-25 | — | — | CN | claimed |
| CN-115108979-B | Preparation method of 8-hydroxyquinoline derivative | 江苏海洋大学 | 2023-07-21 | — | — | CN | claimed |
| CN-115108989-A | Resveratrol derivative and preparation method and application thereof | 山东大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114957312-A | Aryl silicon compound of conjugated olefin and preparation method and application thereof | 南京工业大学 | 2022-08-30 | — | — | CN | claimed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4646200-A1 | HETEROCYCLIC PROPYL AMINE MODULATORS OF MONOAMINERGIC TRANSPORTERS | EmpathBio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-2183232-B1 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7928140-B2 | Benzothiazole PI3 kinase modulators for cancer treatment | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2183232-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | Amgen, Inc (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009017822-A2 | PI3 KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | DYRK1A 4469/4885SMN1; SMN2 4608/4885NPC1 1247/4885 |
| US-20090054405-A1 | PI3 kinase modulators and methods of use | PIK3CA, PIK3C2A, PIK3C2B | DYRK1A 841/4885SMN1; SMN2 3542/4885NPC1 2720/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | DYRK1A 1413/4885SMN1; SMN2 787/4885NPC1 662/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | DYRK1A 1637/4885SMN1; SMN2 4584/4885NPC1 1908/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | DYRK1A 1412/4885SMN1; SMN2 782/4885NPC1 654/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | DYRK1A 20/4885SMN1; SMN2 655/4885NPC1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.